- References (2)
- Inventor Info
|Applications||ELISA IHC IP DB|
|Antigen/Gene or Protein Targets||Cisplatin modified native DNA|
|Relevance||This antibody enables the quantification of cisplatin-induced adducts on DNA. This antibody has also been recently used for isolation of DNA fragments carrying adducts to enhance the sensitivity of subsequent PCR-based analyses and is central to ongoing studies of variation in the nature of cisplatin adducts formed in different cell lines. Antibody CP9/19 recognises only the intra-strand cross-links formed by cisplatin between adjacent purines.|
|Research Area||DNA Damage and Repair, Epigenetics & Nuclear Signalling|
Recombinant monoclonal antibody produced from the original monoclonal. Manufactured using Absolute Antibody’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma.
Three different variants available:
- Anti-Cisplatin modified DNA [CP9/19], Rat IgG2a, Kappa
- Anti-Cisplatin modified DNA [CP9/19], Rat IgG2a, Kappa, containing key point mutations that abrogate binding to Fc gamma receptors
- Anti-Cisplatin modified DNA [CP9/19], Rabbit IgG, Kappa.
There are 2 reference entries for this reagent.View All References